Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
iwCAR-T 2026
The 8th International Workshop on CAR-T and Bispecifics (iwCAR-T)
24–26 April 2026 | Tampa, FL
The 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) took place in Tampa, FL, on April 24-26, 2026, bringing together leading clinical researchers to discuss the latest advances in CAR therapies and bispecific antibodies.
The iwCAR-T and bispecifics 2026 Workshop was supported by Genetech, A2 Bio, Bristol Myers Squibb, Johnson & Johnson, Autolus, Caribou Biosciences, Galapagos, Immatics, Iovance Biotherapeutics, Kite, Legend Biotech, Lyell, Miltenyi Biomedicine and Novartis. Supporters have no influence over the production of content.
CARs targeting cell surface proteins (part I)
Targeting DTP cells to advance CAR T-cell therapy for solid tumors – NSCLC as a model
Elliott Brea Dana-Farber Cancer Institute, Boston, MA, United States
LYL273 for refractory metastatic colorectal cancer
Benjamin Schlechter Dana-Farber Cancer Institute, Boston, MA, United States
Optimizing GPC3 CAR T cells for relapsed/refractory solid tumors
David Steffin Baylor College of Medicine, Houston, TX, United States
Intracerebroventricular dual-targeting CAR T cells for glioblastoma: are we on the right path?
Update in CAR T-cell therapy for breast cancer
Jennifer Specht University of Washington, Seattle, WA, United States
CARs targeting cell surface proteins (part II)
Training T cells for the harsh new world (of solid tumors)
Saul Priceman Keck School of Medicine of USC, Los Angeles, CA, United States
GD2 CAR T cell therapy for H3K27-altered diffuse midline gliomas
Jasia Mahdi Baylor College of Medicine, Houston, TX, United Kingdom
B7H3 CAR-T cell therapy in recurrent platinum resistant epithelial ovarian cancer
Oliver Dorigo Stanford Medicine, Palo Alto, CA, United Kingdom
Innovative allogeneic HER2‑targeted cell therapies: Overcoming barriers in solid tumors
Roisin O’Cearbhaill Memorial Sloan Kettering Cancer Center, New York, NY, United States
Clinical experience with A2B694, a logic‑gated CAR T therapy to treat solid tumors expressing mesothelin
Jeffrey Ward St. Louis, MO, United States
T-cell engagers and TCRs for solid tumors
Mechanisms of T-cell immunogenicity against public neoantigens
Smita Chandran Memorial Sloan Kettering Cancer Center, New York City, United States
Targeting PRAME with TCR-T in advanced melanoma
Targeting cancer testis antigens for synovial sarcoma and myxoid liposarcoma
Michael Wagner Dana-Farber Cancer Institute, Boston, MA, United States
Clinical development of T-cell engagers in prostate cancer: Progress, promise, and pitfalls
Kevin Zarrabi Thomas Jefferson University, Philadelphia, PA, United States
Keynote talk 1
Redefining TIL for the treatment of solid cancer
John Haanen Leiden University, Leiden, Netherlands
TILs for solid tumors
OBX-115 in advanced melanoma
Rodabe Amaria Afghanistan
Coming soon
Enrichment strategies for TIL in NSCLC
TIL sequence in melanoma: Is earlier the right answer?
Daniel Olson University of Chicago, Chicago, IL, United States
Coming soon
What matters in TIL infusion: Product characteristics & outcomes
Lilit Karapetyan Moffitt Cancer Center, Tampa, FL, United States
Novel technologies in solid tumors
Genome-edited anti-GPC3 CAR for hepatoma
Marco Davila Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Coming soon
CAR-M: Engineering myeloid cells for solid tumor immunotherapy
Saar Gill University of Pennsylvania, Philadelphia, PA, United States
Coming soon
Advancing T-cell therapies for solid cancers
Saul Priceman Keck School of Medicine of USC, Los Angeles, CA, United States
Coming soon
